ReviewDermatology and therapy2022
Update on Melasma-Part II: Treatment.
Review in Dermatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and Safety of Ablative Fractional Laser in Melasma: A Meta-analysis and Systematic Review.Lasers in medical science · 2024Pooled it
- Efficacy and safety of metformin for melasma treatment: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial.Scientific reports · 2025Trial
- A Novel Dermocosmetic Routine Containing Vitamin B3 and 2-Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use.Journal of cosmetic dermatology · 2025Trial
- Novel melasma therapy using combined low fluence and microsecond pulse Q switched 1064 nm neodymium doped yttrium aluminium garnet laser.Scientific reports · 2025Trial
- Evaluation of the Efficacy of a Serum Containing Niacinamide, Tranexamic Acid, Vitamin C, and Hydroxy Acid Compared to 4% Hydroquinone in the Management of Melasma.Journal of cosmetic dermatology · 2025Trial
- Retrospective Analysis of the Therapeutic Outcomes of Microneedle Radiofrequency on Melasma by Optical Coherence Tomography: A Observational Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
- Global consensus on the management of melanin hyperpigmentation disorders.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Post-inflammatory Hyperpigmentation in Skin of Color: Emerging Therapies and Treatment Algorithms.Cureus · 2026Review
- Subtype-Specific Response to Fractional-Mode Q-Switched Ruby Laser in Melasma: A Prospective Single-Blind Clinical Study Using Clinical and Noninvasive Imaging Assessments.Clinical, cosmetic and investigational dermatology · 2026Article
- Article
- Efficacy and Tolerability of a New Facial 2-Mercaptonicotinoyl Glycine-Containing Depigmenting Serum Versus Hydroquinone 4% over 3-Month Treatment of Facial Melasma.Dermatology and therapy · 2025Article
- Pathogenesis of Melasma Explained.International journal of dermatology · 2025Review
- Oral tranexamic acid, low-fluence intense pulsed light, and glycolic acid for the treatment of mixed melasma: An observational study.Medicine · 2025Observational
- Dual Benefits of Oral Tranexamic Acid: Reducing Melasma Severity and Inflammation.Journal of cosmetic dermatology · 2025Article
- Latin American consensus on the treatment of melasma.International journal of dermatology · 2025Review
- Role of Polyphenols in Dermatological Diseases: Exploring Pharmacotherapeutic Mechanisms and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Microbial dysbiosis in melasma through community profiling.Frontiers in microbiomes · 2025Article
- Combination of Three Treatment Modes of 1064 nm Nd: YAG Laser in the Treatment of Melasma: A Retrospective Observational Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Energy-Based Methods and Nanocarrier-Based Approaches for Melasma Treatment.Advanced pharmaceutical bulletin · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melasma is a prevalent chronic relapsing pigmentary disorder that affects photoexposed areas, especially in women of childbearing age. Although there is currently no curative treatment available for melasma, this manuscript critically reviews the knowledge regarding photoprotection, topical and oral therapies, and procedures such as peelings, laser, and microneedling that represent the main strategies for control and prevention of this disease. As the pathogenesis of melasma is not entirely understood, there are prospects for the development of new therapeutic strategies that might act on the pathways that promote sustained pigmentation rather than merely decreasing melanin synthesis and removing melanin from the epidermis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.